Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||belantamab mafodotin-blmf + Bortezomib + Dexamethasone|
GSK2857916 is an antibody drug conjugate that targets BCMA antigens on tumor cells, resulting in inhibition of tubulin polymerization and cell cycle arrest, and may have anti-proliferative effect against cancer cells (PMID: 30442502).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|belantamab mafodotin-blmf||Blenrep||anti-BCMA ADC GSK2857916|J6M0-mcMMAF|GSK2857916||TNFRSF17 Antibody 14||Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate comprising an antibody targeting BCMA linked to monomethyl auristatin F, which delivers the anti-microtubule agent to BCMA-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 30442502, PMID: 24569262). Blenrep (belantamab mafodotin-blmf) is FDA approved for use in patients with relapse or refractory multiple myeloma who have received 4 or more prior therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03544281||Phase II||belantamab mafodotin-blmf + Bortezomib + Dexamethasone belantamab mafodotin-blmf + Dexamethasone + Lenalidomide||To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)||Active, not recruiting||USA | ESP | CAN||2|
|NCT04246047||Phase III||belantamab mafodotin-blmf + Bortezomib + Dexamethasone Bortezomib + Daratumumab + Dexamethasone||Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)||Active, not recruiting||USA | ITA | FRA | ESP | DEU | CAN | BEL||13|